Actemra™ Shows Impressive, Consistent Remission Rates

... Three Japanese randomized clinical trials evaluating tocilizumab monotherapy revealed consistent response of tocilizumab in RA patients. Remission rates exceeded 50% at 52 weeks and one study showed 43.3% achievement of ACR70. (Abstract #945). The authors concluded that "targeted blockade of IL-6 signaling is a viable approach to the treatment of RA". [click link for full article] ...